Explore: Biotech · United Kingdom
Thalia Therapeutics
🇬🇧 London, United Kingdom · Founded 2025 · 1-10 employees
UK biotech company that raised €3.1 million and acquired Sanmirna Therapeutics. Thalia Therapeutics is a healthtech and biotech startup based in London, United Kingdom, founded 2025, with $3.3M raised to date.
Thalia Therapeutics is tracked live on Scout, Fusion42's database of newly funded startups — its profile updates as new rounds, backers and Wire analysis land.
Total raised
$3.3M
Business model
transactional
Key differentiator
Their Nuvec® platform based on amorphous silica uniquely enables multi-RNA loading and potential oral delivery, addressing critical RNA delivery inefficiencies.
Target customer
pharmaceutical companies, healthcare providers, and patients with oncology or cardiovascular diseases
Sectors
Notable achievements
- Raised €3.1 million in funding
- Acquired Sanmirna Therapeutics
- Advancing a long-duration, dual-acting siRNA program targeting PCSK9 and lipoprotein(a)
- Renamed from N4 Pharma plc to Thalia Therapeutics plc
Frequently asked questions
- What does Thalia Therapeutics do?
- UK biotech company that raised €3.1 million and acquired Sanmirna Therapeutics.
- Where is Thalia Therapeutics based?
- Thalia Therapeutics is based in London, United Kingdom, founded in 2025.
- How much has Thalia Therapeutics raised?
- Thalia Therapeutics has raised $3.3M in tracked funding.